Introduction to cancer gene therapy

Surgical Oncology Clinics of North America

Volumn 11, Issue 3, 2002, Pages 497-519

  Cusack Jr , James C ^a   Tanabe, Kenneth K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUOROURACIL; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; LIPOSOME; MELAN A; ONYX 015; PLASMID DNA; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; CANCER CONTROL; CANCER GENETICS; CANCER PREVENTION; CANCER RESEARCH; CANCER THERAPY; DRUG RESEARCH; ENZYME THERAPY; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE TECHNOLOGY; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; PHENOTYPE; POXVIRUS; REACTION OPTIMIZATION; RETROVIRUS; REVIEW; SUICIDE GENE THERAPY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VIRAL GENE THERAPY;

CANCER VACCINES; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; NEOPLASMS; ONCOGENIC VIRUSES; TRANSCRIPTION, GENETIC;

EID: 0036660610     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(02)00029-7     Document Type: Review

References (138)

1. Sutherland JV, Bailar III JC. The multihit model of carcinogenesis: Etiologic implications for colon cancer. J Chronic Dis 1984;37:465-80.
2. Goyette M, Cho K, Fasching C, et al. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 1992;12: 1387-95.
3. Cusack Jr JC, Tanabe KK. Cancer gene therapy. Surg Oncol Clin N Am 1998;7:421-69.
4. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
5. Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications. Cancer Res 1991;51:4505-10.
6. Fearon E. Molecular genetics of colorectal cancer. Ann NY Acad Sci 1995;768: 101-10.
7. Ma L, Calvo F. Recent status of the antisense oligonucleotide approaches in oncology. Fundam Clin Pharmacol 1996;10:97-115.
8. Feng M, Cabrera G, Deshane J, Scanlon K, Curiel D. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995; 55:2024-8.
9. Scanlon K, Jiao L, Funato T, Wang W, Tone T. Ribozyme-mediated cleavages of c-fos mRNA reduce gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 1991;88:10591-5.
10. Kashani-Sabet M, Funato T, Florenes V, Fodstad O, Scanlon K. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 1994;54:900-2.
11. Marasco W. Intrabodies: Turning the humoral immune system outside in for intracellular immunization. Gene Ther 1997;4:11-5.
12. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
13. Takahashi T, Carbone D, Nau M, et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992;52:2340-3.
14. Wang J, Bucana C, Roth J, Zhang W. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1995;2:9-17.
15. Clayman GL. The current status of gene therapy. Semin Oncol 2000;27:39-43.
16. Habib NA, Hodgson HJ, Lemoine N, Pignatelli M. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Ther 1999;10:2019-34.
17. Sweeney P, Pisters LL. Ad5CMVp53 gene therapy for locally advanced prostate cancer-where do we stand? World J Urol 2000;18:121-4.
18. Swisher SG, Roth JA, Carbone DP. Genetic and immunologic therapies for lung cancer. Semin Oncol 2002;29:95-101.
19. Fueyo J, Gomez-Manzano C, Yung W, et al. Adenovirus-mediated pl6/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 1996;12:103-10.
20. Xu G, Sun Z, Forrester K, Wang X, Coursen J, Harris C. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 1996;24:1264-8.
21. Lowe S, Ruley H, Jacks T, Housman D. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
22. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W-W, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells by an adenoviral wild-type p53 expression vector. Can Res 1994;54:2287-91.
23. Krasnykh V, Mikheeva G, Douglas J, Curiel D. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996;70:6839-46.
24. Cosset F, Russell S. Targeting retrovirus entry. Gene Ther 1996;3:946-56.
25. Schnierle B, Groner B. Retroviral targeted delivery. Gene Ther 1996;3:1069-73.
26. Cusack JC, Spitz FR, Nguyen D, Zhang W-W, Cristiano RJ, Roth JA. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther 1996;3:245-9.
27. Lee C-H, Liu M, Sie K-L, Lee M-S. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-α and topoisomerase Ilα in prostate cancer. Anticancer Res 1996;16:1805-12.
28. Pang S, Taneja S, Kaboo R, et al. Prostate tissue specificity of the promoter for prostate specific antigen (PSA): Potential approach for the development of target specific gene therapy. In: Gene Therapy. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1994.
29. Richards CA, Wolberg AS, Huber BE. The transcriptional control region of the human carcinoembryonic antigen gene: DNA sequence and homology studies. DNA Seq 1993;4:185-96.
30. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995;6:881-93.
31. Osaki T, Tanio Y, Tachibana I, et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994;54:5258-61.
32. Sakai M, Morinaga T, Urano Y, Watanabe K, Wegmann T, Tamaoki T. The human α-fetoprotein gene. J Biol Chem 1985;260:5055-60.
33. Su H, Chang J, Xu S, Kan Y. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Human Gene Ther. 1996;7:463-70.
34. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumor-specific prodrug activation. Gene Ther 1994;1:170-5.
35. Mullen C. The use of suicide vectors for the gene therapy of cancer. Pharmacol Therapeut 1994;63:199-207.
36. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet 1992;339:715-21.
37. Freeman S, Abboud C, Whartenby K, et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is enetically modified. Cancer Res 1993;53:5274-83.
38. Ishii-Morita H, Agbaria R, Mullen C, et al. Mechanism of "bystander effect" killing in the herpes simplex thymidine kinasegene therapy model of cancer treatment. Gene Ther 1997;4:244-51.
39. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994;91:8302-6.
40. McCormick F. Cancer gene therapy: Fringe or cutting edge? Nat Rev Cancer 2001;1:130-41.
41. Smith ER, Chiocca EA. Oncolytic viruses as novel anticancer agents: Turning one scourge against another. Expert Opin Investig Drugs 2000;9:311-27.
42. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an EIB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.
43. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
44. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an ElB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.
45. Kirn D. Oncolytic virotherapy for cancer with the adenovirus d11520 (Onyx-015): Results of phase I and II trials. Expert Opin Biol Ther 2001;1:525-38.
46. Roizman B. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 1996;93:11307-12.
47. Boviatsis EJ, Chase M, Wei MX, et al. Gene transfer into experimental brain tumors mediated by adenovirus, Herpes Simplex virus, and retrovirus. Human Gene Ther 1994;5:183-91.
48. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988;62:196-205.
49. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996;224:323-30.
50. Rosenberg S, Aebersold P, Cornetta K, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-8.
51. Merrouche Y, Negrier S, Bain C, et al. Clinical application of retroviral gene transfer in oncology: Results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 1995;13:410-8.
52. Mulders P, Tso CL, Pang S, et al. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. J Immunother 1998;21:170-80.
53. Rosenberg SA. Newer approaches to cancer treatment. In: DeVita VTJ, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott Co.; 1993. p. 2598-613.
54. Restifo NP, Spiess PJ, Karp SE, Mule JJ, Rosenberg SA. A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992;175:1423-31.
55. Chang AE, Sondak VK, Bishop DK, Nickoloff BJ, Mulligan RC, Mule JJ. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum Gene Ther 1996;7:773-92.
56. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
57. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumor-igenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989;86:9456-60.
58. Porgador A, Gansbacher B, Bannerji R, et al. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 1993:53:471-7.
59. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
60. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
61. Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta. Ann Surg Oncol 1995;2:151-9.
62. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994;54:5552-5.
63. Sobol RE, Shawler D, Dorigo O, Gold D, Royston I, Fakhrai H. Immunogene therapy of cancer. In: Sobol RE, Scanlong KJ, editors. The Internet Book of Gene Therapy. Stamford: Appleton and Lange; 1995. p. 175-80.
64. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
65. Kim CJ, Prevette T, Cormier J, et al. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother 1997;20:276-86.
66. Cole DJ, Wilson MC, Baron PL, et al. Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. Hum Gene Ther 1996;7:1381-94.
67. Tahara H, Zeh Jr H, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994;54:182-9.
68. Miller A, Miller D, Garcia J, et al. Use of retroviral vectors for gene transfer and expression. Methods Enzymol 1993;217:581-99.
69. Wei R, Gibson M, Spear P, et al. Construction and isolation of transmissible retrovirus containing the SRC gene of harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 2. J Virol 1981;39:935-44.
70. Blaese R. Development of gene therapy for immunodeficiency: Adenosine deaminase deficiency. Pediatr Res 1993;33(Suppl):549-55.
71. Dai Y, Roman M, Naviaux R, et al. Gene therapy via primary myoblasts: Long-term expression of Factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 1992;89:10892-95.
72. van Beusechem V, Kukler A, Heidt P, et al. Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone marrow cells. Proc Natl Acad Sci USA 1992;89:7640-4.
73. Hermann F. Cancer gene therapy: Principles, problems, and perspectives. J Mol Med 1995;73:157-63.
74. Hodgson C. The vector void in gene therapy: Can viral vectors and transfection be combined to permit safe, efficacious, and targeted gene therapy? Biotechnology 1995;13:222-5.
75. Bartholomew R, Esser A, Muller-Eberhard H. Lysis of oncornaviruses by human serum: Isolation of the viral complement (C1) receptor and identification as p15E. J Exp Med 1978;147:844-53.
76. Caruso M, Panis Y, Gagandeep S. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993;90:7024-8.
77. Donahue R, Kessler S, Bodine D, et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviralmediated gene transfer. J Exp Med 1992;176:1125-35.
78. The FDA Points to Consider for Somatic Cell and Gene Therapy CLUtPB. Biologicals Produced by Recombinant DNA Technology and Administration of Activated Leukocytes can be Obtained from the Biologics Information Staff, Office of the Director, Center for Biologics, FDA, Bethesda, MD 20205, USA.
79. Emi N, Friedmann T, Yee JK. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J Virol 1991;65:1202-7.
80. Huber BE, Richards CE, Austin EA. Virus-directed enzyme/prodrug therapy (VDEPT) selectively engineering drug sensitivity into tumors. In: Huber BE, Lazo JS, editors. Gene therapy for neoplastic diseases. Ann NY Acad Sci 1994;716:104-14.
81. Somia N, Zoppé M, Verma I. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery. Proc Natl Acad Sci USA 1995;92:7570-4.
82. Dzierzak E, Papayannopoulou T, Mulligan R. Lineage-specific expression of a human B-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 1988;331:35-41.
83. Episkopou V, Murphy A, Efstratiadis A. Cell-specified expression of a selectable hybrid gene. Proc Natl Acad Sci USA 1984;81:4657-61.
84. Rosenfeld MA, Siegfried W, Yoshimura K, et al. Adenovirus- mediated transfer of a recombinant α 1-antitrypsin gene to the lung epithelium in vivo. Science 1991;252:431-4.
85. Rosenfeld MA, Yoshimura K, Trapnell BC, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992;68:143-55.
86. Stratford-Pericaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992;90:626-30.
87. Setoguchi Y, Jaffe HA, Chu C-S, Crystal RG. Intraperitoneal in vivo genetherapy to deliver 61-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 1994;10:369-77.
88. Quantin B, Perricaudet LD, Tajbakhsh S, Mandel J-L. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 1992;89:2581-4.
89. Jaffe HA, Danel C, Longenecker G, et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver, Nat Genet 1992;1.
90. Li Q, Kay MA, Finegold M, Stratford- Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy, Human Gene Ther 1993;4:403-9.
91. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993;3:219-23.
92. Zabner J, Peterson DM, Puga AP, Graham SM, Welsh MJ. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 1994;6:75-83.
93. Vincent N, Ragot T, Gilgenkrantz H, et al, Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet 1993;5:130-4.
94. Smythe WR, Hwang HC, Elshami AA, et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995;222:78-86.
95. Chen S-H, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994;91:3054-7.
96. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG, In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Human Gene Ther 1995;6:1055-63.
97. Brody SL, Jaffe HA, Han SK, Wersto RP, Crystal RG. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Human Gene Ther 1994;5:437-47.
98. Spitz FR, Nguyen D, Skibber JM, Cusack JC, Roth JA, Cristiano RJ. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 1996;16.
99. Tanaka T, Fumihiko K, Okabe S, et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 1996;56:1341-5.
100. Horwitz M. Adenoviridae and their replication. In: Fields BN, Knipe DM, editors. Virology. 2nd Edition. New York: Raven Press; 1990. p. 1679-712.
101. Ballay A, Levrero M, Buendia M-A, et al. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumen from recombinant human adenoviruses. EMBO J 1985;4:3861-5.
102. Stratford-Perricaudet L, Levrero M, Chasse J-F, et al. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Human Gene Ther 1990;1:241-56.
103. Mittal S, McDermott M, Johnson D, et al, Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res 1993;28:67-90.
104. Ghosh-Choudhury G, Haj-Ahmad Y, Brinkley P, et al. Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene 1986;50:161-71.
105. Englehardt J, Ye X, Doranz B, Wilson J. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994;91:6196-200.
106. Englehardt J, Litzky L, Wilson J. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Human Gene Ther 1994;5:1217-29.
107. Yang Y, Nunes F, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-41.
108. Crystal RG. Transfer of genes to humans: Early lessons and obstacles to success. Science 1995;270:404-10.
109. McGeoch DJ, Dalrymple MA, Dolan A, et al. Structures of herpes simplex virus type 1 genes required for replication of virus DNA. J Virol 1988;62:444-53.
110. Corey L, Spear PG. Infections with herpes simplex viruses (1). N Engl J Med 1986;314:686-91.
111. Steiner I, Kennedy PG. Molecular biology of herpes simplex virus type 1 latency in the nervous system. Mol Neurobiol 1993;7:137-59.
112. Deatly AM, Spivack JG, Lavi E, Fraser NW. RNA from an immediate early region of the type 1 herpes simplex virus genome is present in the trigeminal ganglia of latently infected mice. Proc Natl Acad Sci USA 1987;84:3204-8.
113. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990;82:297-300.
114. Geller AI, Breakefield XO. A defective HSV-1 vector expresses E. coli beta-galactosidase in cultured rat peripheral neurons. Science 1988;241:1667-9.
115. Moss B. Poxviridae and their replication. In: Fields BN, Knipe DM, editors. Virology. 2nd Edition. New York: Raven Press; 1990. p. 2072-99.
116. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341-8.
117. Paoletti E. Applications of pox virus vectors to vaccination: An update. Proc Natl Acad Sci USA 1996;93:11349-53.
118. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987;316:673-6.
119. Wallack MK, Sivanandham M, Ditaranto K, et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine. Ann Surg 1997;226:198-206.
120. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84(14):1084-91.
121. Qin H, Chatterjee SK. Recombinant vaccinia expressing interleukin-2 for cancer gene therapy. Cancer Gene Ther 1996;3:163-7.
122. Berns K, Cheung A, Ostrove J, Lewis M. Adeno-associated virus latent infection. In: Mahy BWJ, Minson AC, Darby GK, editors. Virus Persistence. Cambridge, UK: Cambridge University Press; 1982. p. 249.
123. Flotte T, Afione S, Conrad C, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993;90:10613-7.
124. Samulski R, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991;10:3941-50.
125. Halbert C, Alexander I, Wolgamot G, Miller A. Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells. J Virol 1995;69:1473-9.
126. Kessler P, Podsakoff G, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996;93:14082-7.
127. Nabel E, Gordon D, Yang Z, et al. Gene transfer in vivo with DNA-liposome complexes: Lack of autoimmunity and gonadal localization. Hum Gene Ther 1992;3:649-56.
128. Wagner E, Zenke M, Cotten M, Beug H, Birnstiel M. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci USA 1990;87:3410-4.
129. Kao G, Change L, Allen T. Use of cationic liposomes in enhanced DNA delivery to cancer cells. Cancer Gene Ther 1996;3:250-6.
130. Nabel E, Tang Z, Muller D, et al. Safety and toxicity of catheter delivery to the pulmonary vasculature in a patient with metastatic melanoma. Human Gene Ther 1994;5:1089-94.
131. Cristiano RJ, Smith LC, A KM, Brinkly BR, Woo SL. Hepatic gene therapy: Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 1993;90:11548-52.
132. Bunnell B, Askari F, Wilson J. Targeted delivery of antisense oligonucleotides by molecular conjugates. Somat Cell Mol Genet 1992;18:559-69.
133. Gao L, Wagner E, Cotten M, et al. Direct in vivo gene transfer to airway epithelium employing adenovirus-polylysine-DNA complexes. Hum Gene Ther 1993;4:17-24.
134. Cotten M, Wagner E, Zatloukal K, Philips S, Curiel D, Birnstiel M. High-efficiency receptor mediated delivery of small and large (48 kilbase) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci USA 1992;89:6094-8.
135. Curiel D, Wagner E, Cotten M, et al. High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum Gene Ther 1992;3:147-54.
136. Cristiano R, Roth J. Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther 1996;3:4-10.
137. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000;7:588-92.
138. Anderson WF. Excitement in gene therapy! Hum Gene Ther 2001;12:1483-4.